//
Reslizumab
CAS 241473-69-8
PETAH TIKVA (dpa-AFX) – Teva Pharmaceutical Industries Ltd. (TEVA) Monday said asthma patients with elevated eosinophils showed significant improvement in lung function and asthma control after being treated with reslizumab in final-stage studies of the anti-IL5 monoclonal antibody
read
Reslizumab is a humanized monoclonal antibody intended for the treatment of eosinophil-meditated inflammations of the airways, skinand gastrointestinal tract.[1] As of September 2009, the drug is undergoing Phase II/III clinical trials.[2]
Treatment of bronchial asthma as well as a pharmacological tool to elucidate the role of IL-5 in human eosinophilic diseases
References
- Walsh, GM (2009). “Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions”. Current opinion in molecular therapeutics 11 (3): 329–36. PMID 19479666.
- ClinicalTrials.gov
Filed under: Monoclonal antibody, Phase3 drugs Tagged: Monoclonal Antibodies, Reslizumab, teva
